Genmab A/S (NASDAQ:GMAB) Short Interest Up 40.0% in February

Genmab A/S (NASDAQ:GMAB - Get Free Report) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 2,310,000 shares, an increase of 40.0% from the February 13th total of 1,650,000 shares. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is presently 1.7 days. Currently, 0.4% of the shares of the company are short sold.

Genmab A/S Stock Up 0.2 %

Shares of GMAB stock traded up $0.04 on Wednesday, reaching $20.24. The company had a trading volume of 800,959 shares, compared to its average volume of 906,407. The business's 50-day moving average is $21.18 and its 200 day moving average is $22.28. Genmab A/S has a one year low of $18.64 and a one year high of $31.02. The stock has a market capitalization of $13.40 billion, a PE ratio of 11.63, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, sell-side analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its stake in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares during the last quarter. Lindbrook Capital LLC lifted its holdings in Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after buying an additional 950 shares during the period. GAMMA Investing LLC grew its position in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares during the last quarter. Barclays PLC increased its stake in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC raised its position in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after acquiring an additional 2,496 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on GMAB shares. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Finally, BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $41.33.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.